A Study To Determine Recommended Dose, Regimen And Evaluate The Safety And Preliminary Effectiveness Of CC-92480 In Combination With Standard Treatments In Subjects With Relapsed Or Refractory Multiple Myeloma (RRMM) And Newly Diagnosed Multiple Myeloma (NDMM)

Overview

About this study

The purpose of this study is to determine the maximum tolerated dose (MTD) / recommended phase 2 dose (RP2D), and to evaluate the safety and preliminary effectiveness of CC-92480 in combination with standard treatments.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Subjects is ≥ 18 years of age.
  • Subject has an Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2. 
  • Relapsed or refractory subjects must have measurable disease and have documented disease progression during or after their last anti-myeloma regimen. 
  • Newly diagnosed subjects must have documented diagnosis with previously untreated symptomatic multiple myeloma. 
  • Females of childbearing potential (FCBP) and male subjects must agree with the pregnancy prevention plan.

Exclusion Criteria:

  • Subject is less than 18 years of age.
  • Subject has a significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study. 
  • Subject is unable or unwilling to undergo protocol required thromboembolism prophylaxis.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Wilson Gonsalves, M.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions